Neurocrine Biosciences Reports Positive Phase 2 Data for NBI-1065845 in Adults with Major Depressive Disorder Apr 23, 2024 07:00AM
Takeda and Biological E. Limited Collaborate to Accelerate Access to Dengue Vaccine in Endemic Areas Feb 26, 2024 11:30PM
Arrowhead Pharmaceuticals Reports Fiscal 2023 Third Quarter Results Aug 7, 2023 04:01PM
Arrowhead Presents Updated Data from Phase 2 SEQUOIA Study of Investigational RNAi Therapy Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Liver Disease Jun 24, 2023 08:15AM
Arrowhead Pharmaceuticals Reports Fiscal 2023 Second Quarter Results May 2, 2023 04:01PM
View Older Stories

Apr 4, 2023 07:30AM First Patient Treated in Alpha-1 Antitrypsin Deficiency Liver Disease Phase 3 Study Triggering $40 Million Milestone Payment from Takeda to Arrowhead
Mar 1, 2023 08:30AM Hannon Armstrong Appoints Former EXIM Chairman Kimberly A. Reed and CEO Jeffrey A. Lipson to Board of Directors
Jan 9, 2023 07:30AM Arrowhead and Takeda Announce Topline Results from SEQUOIA Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Dec 21, 2022 08:00PM Astellas, Eisai, Daiichi Sankyo and Takeda Agree to Collaborate to Reduce Environmental Burden in the Field of Pharmaceutical Packaging
Dec 6, 2022 12:00AM Global pharma giants partner Singapore researchers to boost innovation in biologics and vaccines manufacturing
Sep 19, 2022 08:00AM Takeda Signs Virtual Power Purchase Agreement with Enel North America to Advance Renewable Energy Production in the United States
Jun 27, 2022 06:00AM Results from Phase 2 Study of Fazirsiran in Patients with Alpha-1 Antitrypsin Deficiency Published in New England Journal of Medicine
Jun 5, 2022 08:00AM NEW HEAD-TO-HEAD DATA SHOW VECTIBIX® (PANITUMUMAB) DEMONSTRATED SUPERIOR OVERALL SURVIVAL COMPARED TO BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN JAPANESE PATIENTS WITH WILD-TYPE RAS COLORECTAL C
May 26, 2022 05:25PM Takeda and Seagen to Highlight ADCETRIS® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma
Sep 21, 2021 08:06AM Mirum Pharmaceuticals (MIRM), Takeda (TAK) Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Sep 21, 2021 08:00AM Mirum Pharmaceuticals and Takeda Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat for Rare Pediatric Liver Diseases in Japan
Mar 1, 2021 12:35PM The Children's National Hospital Rare Disease Institute And Takeda Partner To Standardize Care For Patients With Rare Diseases
Dec 16, 2020 09:00AM Prime Therapeutics and Takeda agree to outcomes-based arrangement for Hemophilia A treatment ADVATE® [Antihemophilic Factor (Recombinant)]
Nov 30, 2020 04:45PM World's Leading Life Science Companies Now Enrolling COMMUNITY, A Global, Platform Trial For Hospitalized Patients With COVID-19
Oct 8, 2020 07:32AM Takeda (TAK) and Arrowhead (ARWR) Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Oct 8, 2020 07:30AM Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Sep 18, 2020 06:56AM Foundation Medicine and Takeda Announce Collaboration To Develop FoundationOne®CDx and FoundationOne®Liquid CDx as Companion Diagnostics for Takeda’s Late-Stage Lung Cancer Portfolio
Aug 7, 2020 06:18AM Novavax (NVAX) and Takeda (TAK) Announce Collaboration for Novavax' COVID-19 Vaccine Candidate in Japan
Aug 7, 2020 05:28AM Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Aug 7, 2020 05:26AM Novavax and Takeda Announce Collaboration for Novavax’ COVID-19 Vaccine Candidate in Japan
Aug 3, 2020 07:30AM Members Of The COVID R&D Alliance And Quantum Leap Healthcare Collaborative Enroll First Patients In I-SPY COVID Trial
Dec 9, 2019 10:03AM Seattle Genetics (SGEN), Takeda (TAK) Announce Additional Analyses of ADCETRIS ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at ASH
Dec 9, 2019 10:00AM Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Dec 9, 2019 10:00AM Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting
Jun 27, 2019 05:22AM Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program, Supporting Disease Prevention to Improve Health in Developing and Emerging Countries
Dec 3, 2018 09:15PM Seattle Genetics and Takeda Present Positive Data from Phase 3 ECHELON-2 Clinical Trial for ADCETRIS® (Brentuximab Vedotin) in Frontline Treatment of CD30-Expressing Peripheral T-Cell Lymphomas
Oct 22, 2018 08:55AM New Data Added to TRINTELLIX® (vortioxetine) Labeling Demonstrated Superiority Over Escitalopram in Improving SSRI-Induced Sexual Dysfunction in Patients with Major Depressive Disorder
Oct 1, 2018 06:48AM Seattle Genetics (SGEN), Takeda Pharmaceutical Report Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS (Brentuximab Vedotin)
Oct 1, 2018 06:45AM Seattle Genetics and Takeda Announce Positive Results from Phase 3 ECHELON-2 Clinical Trial Evaluating ADCETRIS® (Brentuximab Vedotin) in Frontline CD30-Expressing Peripheral T-Cell Lymphoma
May 2, 2018 05:36PM TRINTELLIX® (vortioxetine) Prescribing Information Now Includes New Data Showing Improvement in Processing Speed, an Important Aspect of Cognitive Function in Acute Major Depressive Disorder (MDD)
Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Dec 10, 2017 08:00AM Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma
Nov 8, 2017 09:00AM Takeda Recognizes ALK+ Day with Launch of tALK+ Initiative During November’s Lung Cancer Awareness Month
Nov 7, 2017 07:00AM Takeda and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device
Nov 6, 2017 10:00AM Takeda, Lundbeck and Advocate Health Care Research Study Aims to Enhance Patient-Provider Engagement in Major Depressive Disorder Treatment using Digital Technology
Oct 30, 2017 08:00AM Takeda and the New York Academy of Sciences Announce Innovators in Science Award Honorees
Sep 26, 2017 09:00AM Takeda Named To 2017 Working Mother "100 Best Companies" For Leadership In Family Benefits And Paid Leave
Jan 30, 2017 06:00PM Exelixis and Takeda Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Japan
Jan 9, 2017 08:02AM ARIAD Enters into Definitive Agreement to Be Acquired by Takeda for $5.2 Billion
Nov 10, 2016 08:00AM Takeda and the New York Academy of Sciences to Honor Commitment to Innovation in Key Areas of Therapeutic Focus
Jun 1, 2016 10:00AM Trintellix (vortioxetine) Now Available in U.S. Pharmacies
May 16, 2016 04:01PM Takeda and Lundbeck Present Vortioxetine Data at the American Psychiatric Association (APA) 2016 Annual Meeting
May 2, 2016 03:32PM Brintellix (vortioxetine) Renamed Trintellix (vortioxetine) in U.S. to Avoid Name Confusion
Mar 28, 2016 08:02PM Takeda and Lundbeck Receive Complete Response Letter for Brintellix® (vortioxetine) sNDA
Feb 3, 2016 08:36PM FDA Psychopharmacologic Drug Advisory Committee Supports the Effectiveness of Brintellix® (vortioxetine) in Treating Certain Aspects of Cognitive Dysfunction in Major Depressive Disorder (MDD)
Aug 10, 2015 06:36PM FDA Accepts a Supplemental New Drug Application for Review of Brintellix® (vortioxetine) Clinical Trial Data That Assessed Cognitive Function in Patients with Major Depressive Disorder
Mar 14, 2014 05:29PM Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
View Older Stories